Bridget Marcellino is an Oncology physician affiliated with Mount Sinai Medical Center. OpenAlex indexes 84 publications with 872 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Gustave L Levy Pl
New York, NY 100296504
Telephone
212-241-6756Provider last certified this registry record 9 Jan 2020.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20251 payment
- GENZYME CORPORATIONProgram year20251 payment
- Incyte CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
62.5%Azole Antifungal35%Posaconazole100%Part D<11 patientsFluoroquinolone Antibacterial27.5%Levofloxacin100%Part D<11 patientsDermatology
37.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor37.5%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- The Role of PPM1D in Myeloproliferative Neoplasms
Icahn School of Medicine at Mount Sinai
FY2026$118,602K08HL163489
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Inflammatory Bowel Diseases
2025 - Metabolic adaptations to acute glucose uptake inhibition converge upon mitochondrial respiration for leukemia cell survival
Cell Communication and Signaling
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Edward Wolin, MD
Mount Sinai Medical Center
David Nierman, MD
Mount Sinai Medical Center
Jaya Ganesh, MD
Mount Sinai Medical Center
Efsevia Albanis, MD
Mount Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”